Don’t tell Plexxikon there’s no money left in investors’ pockets. The Berkeley, Calif.-based company recently closed a $27 million funding round led by Walden International.

Founded in 1999 by a team of scientists with expertise in cell signaling proteins and their potential as drug targets, Plexxikon differentiates itself from structural proteomics competitors such as Syrrx, Structural Genomix, and big pharma companies by not pursuing a high-throughput crystallography approach.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The data generated by 100,000 Genomes Project is being housed on military servers due to attacks by hackers, Naked Security reports.

A new poll finds most US adults are not familiar with personalized medicine, according to HealthDay.

Vox reports that the United Nations' Convention on Biological Diversity decided against a gene drive moratorium.

In Science this week: sequencing of neuroblastomas uncovers alterations linked to prognosis, and more.